• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    1/13/23 4:46:55 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    SC 13G/A 1 d308958dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1*)

     

     

    DiaMedica Therapeutics Inc.

    (Name of Issuer)

    Voting Common Shares, no par value per share

    (Title of Class of Securities)

    25253X207

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No 25253X207    Page 2 of 6

     

     

      (1)    

      Names of reporting persons

     

      Richard Jacinto II

      (2)  

      Check the appropriate box if a member of a group (see instructions)

     

      (a)  ☐        (b)  ☐

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      United States

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole Voting Power

     

      2,500,000 voting common shares (1)

       (6)  

      Shared Voting Power

     

      0

       (7)  

      Sole Dispositive Power

     

      2,500,000 voting common shares (1)

       (8)  

      Shared Dispositive Power

     

      0

      (9)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,500,000 voting common shares (1)

    (10)  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    (11)  

      Percent of Class Represented by Amount in Row (9)

     

      9.5% (2)

    (12)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 100,000 voting common shares held by Fidelity Roth IRA Richard Jacinto II – Roth IRA – FMTC Custodian, of which Richard Jacinto II is the beneficiary, and (ii) 2,400,000 voting common shares held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

    (2)

    Based on 26,443,067 voting common shares of the Issuer outstanding as of November 7, 2022.


    CUSIP No 25253X207    Page 3 of 6

     

    Item 1(a).

    Name of Issuer:

    DiaMedica Therapeutics Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    301 Carlson Parkway, Suite 210, Minnetonka, Minnesota 55305    

     

    Item 2(a).

    Name of Person Filing:

    Richard Jacinto II

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The Reporting Person’s address is 394 Saddle Back Trail, Franklin Lakes, NJ 07417.

     

    Item 2(c).

    Citizenship:

    United States

     

    Item 2(d).

    Title of Class of Securities:

    Voting Common Shares, no par value per share

     

    Item 2(e).

    CUSIP No.:

    25253X207

     

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    [    ]    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       (b)    [    ]    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       (c)    [    ]    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       (d)    [    ]    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
       (e)    [    ]    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    [    ]    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    [    ]    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);


    CUSIP No 25253X207

     

       Page 4 of 6

     

                    (h)    [    ]    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    [    ]    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    [    ]    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
       (k)    [    ]    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4. Ownership

     

    (a)

    Amount beneficially owned: 2,500,000 voting common shares (1)

     

    (b)

    Percent of class: 9.5% (2)

     

    (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: 2,500,000 voting common shares (1)

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 2,500,000 voting common shares (1)

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    (1)

    Consists of (i) 100,000 voting common shares held by Fidelity Roth IRA Richard Jacinto II – Roth IRA – FMTC Custodian, of which Richard Jacinto II is the beneficiary, and (ii) 2,400,000 voting common shares held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

    (2)

    Based on 26,443,067 voting common shares of the Issuer outstanding as of November 7, 2022.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.


    CUSIP No 25253X207    Page 5 of 6

     

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No 25253X207    Page 6 of 6

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 13, 2023

     

    By:  

    /s/ Richard Jacinto II

    Name:   Richard Jacinto II
    Get the next $DMAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Stahlberg Jan bought $5,400,000 worth of shares (1,542,857 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 6:54:18 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Von Koch Thomas bought $9,999,997 worth of shares (2,857,142 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 5:49:44 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Jacinto Richard Ii bought $1,400,000 worth of Voting Common Shares (400,000 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 4:35:02 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Enrollment for ReMEDy2 Phase 2/3 Trial Progressing with Interim Data Anticipated in Q2 2026 Inclusion in the Russell 2000® and 3000® Indexes Appointment of Julie Krop, MD, to Chief Medical Officer Conference Call and Webcast August 13 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage

    8/12/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te

    8/6/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, August 13, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/BMb9EBAwZYP Dial In: (800) 836-8184 Con

    8/5/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Stahlberg Jan bought $5,400,000 worth of shares (1,542,857 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 6:54:18 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Von Koch Thomas bought $9,999,997 worth of shares (2,857,142 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 5:49:44 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Jacinto Richard Ii bought $1,400,000 worth of Voting Common Shares (400,000 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 4:35:02 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    SEC Filings

    View All

    DiaMedica Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    8/12/25 5:27:58 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by DiaMedica Therapeutics Inc.

    S-3 - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    8/12/25 5:09:56 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by DiaMedica Therapeutics Inc.

    10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    8/12/25 4:17:13 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

    H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

    10/7/24 7:50:42 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

    Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00

    4/24/24 8:38:29 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00

    6/22/23 7:34:26 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te

    8/6/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

    2/24/25 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Financials

    Live finance-specific insights

    View All

    DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Enrollment for ReMEDy2 Phase 2/3 Trial Progressing with Interim Data Anticipated in Q2 2026 Inclusion in the Russell 2000® and 3000® Indexes Appointment of Julie Krop, MD, to Chief Medical Officer Conference Call and Webcast August 13 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage

    8/12/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, August 13, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/BMb9EBAwZYP Dial In: (800) 836-8184 Con

    8/5/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

    Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barrier and was Generally Safe and Well Tolerated Highly Statistically Significant Reduction in Uterine Artery Pulsatility Index Robust Evidence Supports a Potential Best-In-Class Mechanism Enhancing Placental Perfusion, Protecting the Endothelium and Reducing Blood Pressure DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Par

    7/17/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

    SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    7/8/24 5:23:49 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:12:06 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:11:32 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care